Boston, MA- and Tel-Aviv-based InspireMD Inc. is making progress with its proprietary emboli-trapping InspireMD Embolic Protection Stent (EPS) platform technology for use primarily in patients with embolic-risk acute coronary syndromes, such as myocardial infarction (AMI) and saphenous vein graft coronary interventions. The device has an expandable MicroNet, an ultrathin, circular-knitted polyethylene terephthalate (PET) micron mesh sleeve attached to the proximal and distal edges of the stent, covering 20% of its surface. The MicroNet is designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization – a major issue with ST segment elevation myocardial infarction (STEMI) patients – without affecting stent deliverability or deployment. The original histology work for the mesh technology was done at the Massachusetts Institute of Technology under the direction of Elazer Edelman, MD, PhD, a prominent cardiologist at Brigham and Women's Hospital in Boston.
"Ours is the first simple, integrated stent system focused on myocardial salvage and mortality improvement that has delivered early, very...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?